007570 — Ilyang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapSucker Stock

Annual income statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS/A	ARS/A	ARS/A	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	242,511	247,773	266,669	268,678	272,422
Cost of Revenue
Gross Profit	104,750	108,310	116,493	111,292	116,355
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	227,031	233,549	266,750	259,053	267,415
Operating Profit	15,481	14,223	-80.8	9,625	5,008
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	22,063	23,846	-1,799	10,899	13,260
Provision for Income Taxes
Net Income After Taxes	14,752	19,806	-2,030	9,282	7,133
Minority Interest
Net Income Before Extraordinary Items
Net Income	14,032	19,385	-2,409	9,032	6,905
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14,032	18,933	-2,365	8,803	6,727
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	761	1,045	463	490	371
Dividends per Share